$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000094480922000047 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$185.3M	$179.7M	$385.8M
YoY Change	-53.82%	-53.41%	-9.87%
Cost Of Revenue	$129.3M	$148.4M	$244.0M
YoY Change	-55.83%	-39.15%	-10.57%
Gross Profit	$55.99M	$31.30M	$141.9M
YoY Change	-48.4%	-77.94%	-8.66%
Gross Profit Margin	30.21%	17.41%	36.77%
Selling, General & Admin	$74.00M	$79.67M	$105.1M
YoY Change	-46.46%	-24.21%	5.23%
% of Gross Profit	132.15%	254.56%	74.1%
Research & Development	$19.53M	$18.79M	$18.31M
YoY Change	-7.04%	2.65%	-1.01%
% of Gross Profit	34.88%	60.04%	12.9%
Depreciation & Amortization	$26.46M	$28.00M	$18.96M
YoY Change	37.88%	47.63%	-9.85%
% of Gross Profit	47.26%	89.44%	13.37%
Operating Expenses	$240.6M	$267.6M	$348.0M
YoY Change	-48.19%	-23.11%	-14.32%
Operating Profit	-$184.6M	-$87.82M	$37.83M
YoY Change	-48.13%	-332.17%	72.41%
Interest Expense	-$2.162M	-$1.904M	-$2.998M
YoY Change	-46.3%	-36.49%	-50.03%
% of Operating Profit			-7.93%
Other Income/Expense, Net	-$44.75M	-$38.56M	-$6.354M
YoY Change	-3550.35%	506.78%	392.56%
Pretax Income	-$102.2M	-$126.4M	$31.47M
YoY Change	55.26%	-501.55%	52.41%
Income Tax	-$16.98M	-$40.33M	$2.680M
% Of Pretax Income			8.52%
Net Earnings	-$85.23M	-$86.09M	$28.74M
YoY Change	15.53%	-399.56%	21.17%
Net Earnings / Revenue	-45.99%	-47.9%	7.45%
Basic Earnings Per Share	-$0.11	-$0.11	$0.04
Diluted Earnings Per Share	-$0.11	-$0.11	$0.04
COMMON SHARES
Basic Shares Outstanding	772.7M shares	772.0M shares	651.8M shares
Diluted Shares Outstanding		750.4M shares	651.8M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.2M	$180.8M	$148.6M
YoY Change	13.72%	21.7%	309.36%
Cash & Equivalents	$153.2M	$180.8M	$148.6M
Short-Term Investments
Other Short-Term Assets	$6.252M	$6.340M	$11.00M
YoY Change	0.92%	-42.38%	45.89%
Inventory	$74.06M	$71.43M	$112.9M
Prepaid Expenses
Receivables	$127.3M	$123.2M	$255.2M
Other Receivables	$21.30M	$15.06M	$10.33M
Total Short-Term Assets	$394.5M	$414.0M	$557.5M
YoY Change	-52.06%	-25.75%	30.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.6M	$119.7M	$141.0M
YoY Change	-1.9%	-15.08%	5.15%
Goodwill	$595.9M	$573.5M	$674.6M
YoY Change	14.45%	-14.98%	-0.18%
Intangibles	$823.5M
YoY Change
Long-Term Investments	$28.08M	$77.80M	$11.75M
YoY Change	161.72%	561.99%	-17.81%
Other Assets	$8.679M	$9.636M	$8.744M
YoY Change	-8.97%	10.2%	49.29%
Total Long-Term Assets	$1.773B	$1.811B	$1.860B
YoY Change	12.43%	-2.65%	-4.27%
TOTAL ASSETS
Total Short-Term Assets	$394.5M	$414.0M	$557.5M
Total Long-Term Assets	$1.773B	$1.811B	$1.860B
Total Assets	$2.167B	$2.225B	$2.418B
YoY Change	-9.69%	-7.98%	1.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$66.99M	$49.75M	$94.39M
YoY Change	-18.34%	-47.3%	43.71%
Accrued Expenses	$98.27M	$112.0M	$163.9M
YoY Change	-49.21%	-31.67%	-34.01%
Deferred Revenue	$0.00	$257.0K	$3.004M
YoY Change	-100.0%	-91.44%	-78.69%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$39.40M	$96.55M	$16.70M
YoY Change	132.42%	478.1%	11.35%
Total Short-Term Liabilities	$213.5M	$267.3M	$283.0M
YoY Change	-35.31%	-5.57%	-15.74%
LONG-TERM LIABILITIES
Long-Term Debt	$226.6M	$155.1M	$1.671M
YoY Change	17.34%	9183.96%	-58.33%
Other Long-Term Liabilities	$27.37M	$22.55M	$20.99M
YoY Change	81.72%	7.44%	-53.39%
Total Long-Term Liabilities	$392.1M	$328.4M	$369.0M
YoY Change	1.96%	-11.0%	-10.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$213.5M	$267.3M	$283.0M
Total Long-Term Liabilities	$392.1M	$328.4M	$369.0M
Total Liabilities	$605.6M	$595.7M	$652.1M
YoY Change	-15.25%	-8.64%	-12.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.823B	-$1.738B	-$1.438B
YoY Change	20.57%	20.82%	-5.01%
Common Stock	$7.813M	$7.814M	$6.900M
YoY Change	13.22%	13.25%	2.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$1.791M
YoY Change			0.0%
Treasury Stock Shares			8.655M shares
Shareholders Equity	$1.562B	$1.629B	$1.766B
YoY Change
Total Liabilities & Shareholders Equity	$2.167B	$2.225B	$2.418B
YoY Change	-9.69%	-7.98%	1.95%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$85.23M	-$86.09M	$28.74M
YoY Change	15.53%	-399.56%	21.17%
Depreciation, Depletion And Amortization	$26.46M	$28.00M	$18.96M
YoY Change	37.88%	47.63%	-9.85%
Cash From Operating Activities	-$31.62M	-$32.24M	$33.40M
YoY Change	460.34%	-196.53%	-46.99%
INVESTING ACTIVITIES
Capital Expenditures	$6.336M	-$7.612M	-$7.234M
YoY Change	-194.15%	5.23%	-26.18%
Acquisitions
YoY Change
Other Investing Activities	-$1.536M	$2.930M	$61.81M
YoY Change	-21.19%	-95.26%	306.64%
Cash From Investing Activities	-$7.872M	-$4.682M	$54.58M
YoY Change	-9.3%	-108.58%	892.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.14M	8.444M	-4.256M
YoY Change	1119.23%	-298.4%	-92.19%
NET CHANGE
Cash From Operating Activities	-31.62M	-32.24M	33.40M
Cash From Investing Activities	-7.872M	-4.682M	54.58M
Cash From Financing Activities	10.14M	8.444M	-4.256M
Net Change In Cash	-29.35M	-28.47M	83.72M
YoY Change	117.55%	-134.01%	497.97%
FREE CASH FLOW
Cash From Operating Activities	-$31.62M	-$32.24M	$33.40M
Capital Expenditures	$6.336M	-$7.612M	-$7.234M
Free Cash Flow	-$37.96M	-$24.62M	$40.63M
YoY Change	-3591.81%	-160.61%	-44.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33528
	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	575-4100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	OPK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	772685879	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	180838000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134710000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123188000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	259637000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	71429000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	86502000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38516000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27170000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	0	usd
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	314994000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	413971000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	823013000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79949000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79727000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	835136000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	321683000	usd
CY2022Q3	opk	In Process Researchand Development InProcessResearchandDevelopment	195000000	usd
CY2021Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	573499000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	520601000	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	77804000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	10729000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39790000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44228000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9636000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9534000	usd
CY2022Q3	us-gaap	Assets Assets	2224785000	usd
CY2021Q4	us-gaap	Assets Assets	2399715000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	49748000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	82040000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112015000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193493000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11535000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11624000	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	70632000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28156000	usd
CY2022Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	23342000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	14695000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	267272000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	330008000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29005000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33097000	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	141815000	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	187935000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	135073000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	148487000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22552000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15062000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	328445000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	384581000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	595717000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	714589000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781341231	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	690082283	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7814000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6901000	usd
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082	shares
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082	shares
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3418763000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3222487000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-58026000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30495000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1737692000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1511976000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1629068000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1685126000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2224785000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2399715000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179744000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	385813000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	818856000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1373387000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79674000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	105120000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	298675000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	330643000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18792000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18306000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54359000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55843000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-754000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-497000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-685000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1556000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21407000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12609000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66225000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37760000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	31508000	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	15365000	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	31508000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	267564000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	347987000	usd
	us-gaap	Operating Expenses OperatingExpenses	989840000	usd
	us-gaap	Operating Expenses OperatingExpenses	1291553000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-87820000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37826000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-170984000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	81834000	usd
CY2022Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	667000	usd
CY2021Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	9000	usd
	opk	Interest Income Nonoperating InterestIncomeNonoperating	838000	usd
	opk	Interest Income Nonoperating InterestIncomeNonoperating	21000	usd
CY2022Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	3017000	usd
CY2021Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	4290000	usd
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	8754000	usd
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	14572000	usd
CY2022Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	446000	usd
CY2021Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1283000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	652000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	571000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-36651000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3356000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-111091000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16067000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38555000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6354000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-118355000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30047000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-126375000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	31472000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-289339000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	51787000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-40327000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-46524000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7993000	usd
CY2022Q3	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	-86048000	usd
CY2021Q3	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	28792000	usd
	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	-242815000	usd
	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	43794000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	usd
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-53000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-359000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-163000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-86091000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-243174000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43631000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	750396263	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	750396263	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651843074	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651843074	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	708121980	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	708121980	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	646710240	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	646710240	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-86091000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-243174000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43631000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8855000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9991000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-27531000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-15698000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94946000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18748000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-270705000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27933000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1718799000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3390000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-463000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1765567000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9929000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2288000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-86091000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8855000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1629068000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1685126000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15315000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-688000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	221662000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-243174000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27531000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1629068000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1742585000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3822000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	412000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9991000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	879000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	55275000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43631000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15698000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1765567000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-243174000	usd
	us-gaap	Net Income Loss NetIncomeLoss	43631000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82195000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59525000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	2057000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	7164000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	863000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	603000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-359000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-163000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	15315000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9929000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	814000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	35484000	usd
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	0	usd
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-11111000	usd
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-104126000	usd
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1919000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-685000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1556000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	15365000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-48883000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2378000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-130052000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27934000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11314000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14254000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3977000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13738000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-211000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1015000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-25000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4746000	usd
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	10541000	usd
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	2382000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-73000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13016000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-82631000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-65687000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63569000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	43980000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8079000	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	115423000	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-228000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4000000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1501000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	65975000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	18242000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	25426000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	98910000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44628000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	188000	usd
	opk	Proceeds From Stock Options Exercised Net Of Tax Withholdings ProceedsFromStockOptionsExercisedNetOfTaxWithholdings	-688000	usd
	opk	Proceeds From Stock Options Exercised Net Of Tax Withholdings ProceedsFromStockOptionsExercisedNetOfTaxWithholdings	879000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	893548000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1326641000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	880033000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1338515000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12827000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11183000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2040000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-163000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46128000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	76388000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134710000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72211000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180838000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148599000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7019000	usd
	us-gaap	Interest Paid Net InterestPaidNet	8386000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4471000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5509000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	68775000	usd
	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	1182000	usd
	opk	Common Stock Warrants Net Exercised CommonStockWarrantsNetExercised	0	usd
	us-gaap	Stock Issued1 StockIssued1	221662000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	172000000	usd
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	0	usd
	opk	Numberof Sales Employees NumberofSalesEmployees	180	employee
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	54600000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	27100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span>liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	3000000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	4000000	usd
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	1300000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5300000	usd
CY2022Q3	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1600000000	usd
CY2021Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1400000000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	573500000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	520600000	usd
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	900000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66200000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37800000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	5000000	usd
	us-gaap	Depreciation Depreciation	16000000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	6400000	usd
	us-gaap	Depreciation Depreciation	21800000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6400000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1800000	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	57900	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	241500	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	29300	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	636100	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15300000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9900000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7600000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5600000	usd
CY2022Q3	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	27750	shares
CY2022Q3	opk	Stock Issued During Period Shares Restricted Stock Units Exercised StockIssuedDuringPeriodSharesRestrictedStockUnitsExercised	937836	shares
CY2022Q3	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	749550	shares
CY2022Q3	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised	965586	shares
CY2022Q3	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	216036	shares
	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	211187	shares
	opk	Stock Issued During Period Shares Restricted Stock Units Exercised StockIssuedDuringPeriodSharesRestrictedStockUnitsExercised	1599212	shares
	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	1351637	shares
	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercised	1810399	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	458762	shares
CY2021Q3	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	178687	shares
CY2021Q3	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	178687	shares
CY2021Q3	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	178687	shares
CY2021Q3	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	358812	shares
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1615000	usd
	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	358812	shares
	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	358812	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	129576000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	261476000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6388000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1839000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123188000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	259637000	usd
CY2022Q3	us-gaap	Other Inventory Supplies OtherInventorySupplies	30211000	usd
CY2021Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	39447000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	37188000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44107000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2580000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6417000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6112000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4967000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4779000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	71429000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	86502000	usd
CY2022Q3	opk	Taxes Recoverable Current TaxesRecoverableCurrent	5161000	usd
CY2021Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	5598000	usd
CY2022Q3	us-gaap	Supplies Supplies	9785000	usd
CY2021Q4	us-gaap	Supplies Supplies	10641000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	7331000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4383000	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9899000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	353000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	6340000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6195000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38516000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27170000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	366921000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	320820000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	835136000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	321683000	usd
CY2022Q3	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	13545000	usd
CY2021Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	40446000	usd
CY2022Q3	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	1647000	usd
CY2021Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	27819000	usd
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	45124000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	45939000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	257000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	258000	usd
CY2022Q3	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4073000	usd
CY2021Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4867000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2580000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2257000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1630000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2121000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	43159000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69299000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112015000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193493000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1671000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2350000	usd
CY2022Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	8970000	usd
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	2224000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4350000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2924000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	136000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	208000	usd
CY2022Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	7425000	usd
CY2021Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	7356000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22552000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15062000	usd
CY2022Q1	us-gaap	Goodwill Goodwill	710408000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	usd
	opk	Goodwill Acquired Disposed Of During Period GoodwillAcquiredDisposedOfDuringPeriod	-85919000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-12966000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	573499000	usd
CY2022Q3	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	141000	usd
CY2022Q3	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2623000	usd
CY2021Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	263000	usd
CY2021Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	3577000	usd
CY2022Q3	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	786000	usd
CY2022Q3	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	1920000	usd
CY2021Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	816000	usd
CY2021Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	3043000	usd
CY2022Q3	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	70240000	usd
CY2021Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	0	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1227000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4226000	usd
CY2022Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5389000	usd
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5408000	usd
CY2022Q3	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	21000	usd
CY2021Q4	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	16000	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	77804000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	10729000	usd
CY2022Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	1500000	usd
CY2021Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	4500000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-2999000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	491000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2981000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-2999000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-2490000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	244981000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	205272000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	244981000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	205272000	usd
CY2022Q3	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	13	institution
CY2021Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2022Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	104780000	usd
CY2022Q3	us-gaap	Line Of Credit LineOfCredit	21850000	usd
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	13672000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	129312000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1227000	usd
CY2022Q3	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	70240000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	201134000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1671000	usd
CY2022Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1671000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4226000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4364000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2837000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2837000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1700000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2800000	usd
CY2022Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	31000	usd
CY2021Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	usd
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	43000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1700000	usd
CY2022Q3	opk	Litigation Settlement Corporate Integrity Agreement Term LitigationSettlementCorporateIntegrityAgreementTerm	P5Y
CY2022Q3	us-gaap	Purchase Obligation PurchaseObligation	84100000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	27800000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	36000000	usd
CY2022Q3	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	1300000	usd
CY2021Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	5000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	466000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	393000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	73000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-87820000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37826000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-170984000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	81834000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27995000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18963000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82195000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59525000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-43000	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-53000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-359000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-163000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179744000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	385813000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	818856000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1373387000	usd
CY2022Q3	us-gaap	Assets Assets	2224785000	usd
CY2021Q4	us-gaap	Assets Assets	2399715000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	573499000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	520601000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39790000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44228000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6930000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5181000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11535000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11624000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2580000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2257000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29005000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33097000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4350000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2924000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.037
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.076
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.048
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3152000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	868000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10435000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2501000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7111000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1928000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4739000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1405000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3775000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	746000	usd
CY2022Q3	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	15568000	usd
CY2022Q3	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	10000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	44780000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	7458000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4240000	usd
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	528000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	40540000	usd
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	6930000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	12500000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2000000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	13400000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1700000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1400000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	12312000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	12278000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	106000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	101000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1020000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1498000	usd
	opk	Payments For Leases PaymentsForLeases	13438000	usd
	opk	Payments For Leases PaymentsForLeases	13877000	usd

Files In Submission

Name	View Source	Status
0000944809-22-000047-index-headers.html	Edgar Link	pending
0000944809-22-000047-index.html	Edgar Link	pending
0000944809-22-000047.txt	Edgar Link	pending
0000944809-22-000047-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20220930.htm	Edgar Link	pending
opk-20220930.xsd	Edgar Link	pending
opk-9302022xex311.htm	Edgar Link	pending
opk-9302022xex312.htm	Edgar Link	pending
opk-9302022xex321.htm	Edgar Link	pending
opk-9302022xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
opk-20220930_def.xml	Edgar Link	unprocessable
opk-20220930_cal.xml	Edgar Link	unprocessable
opk-20220930_pre.xml	Edgar Link	unprocessable
opk-20220930_lab.xml	Edgar Link	unprocessable
opk-20220930_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2022 Q4 Form 10-Q Financial Statement

#000094480922000047 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2022 Q4 Form 10-Q Financial Statement

#000094480922000047 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk